Veraxa Biotech AG Income Statement

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Selling, General & Admin	20.73	10.55
Research & Development	6.31	4.26
Operating Expenses	28.92	16.66
Operating Income	-28.92	-16.66
Interest Expense	-0	-0
Currency Exchange Gain (Loss)	0.62	-1.05
Other Non Operating Income (Expenses)	0.01	0.05
EBT Excluding Unusual Items	-28.28	-17.66
Other Unusual Items	-0.47	-
Pretax Income	-28.75	-17.66
Income Tax Expense	-0.62	-1.11
Net Income	-28.13	-16.54
Net Income to Common	-28.13	-16.54
Net Income Growth	-	-
Shares Outstanding (Basic)	14	14
Shares Outstanding (Diluted)	14	14
Shares Change	2.36%	-
EPS (Basic)	-2.00	-1.21
EPS (Diluted)	-2.00	-1.21
EPS Growth	-	-

Additional Metrics

SEC Filings: 10-K · 10-Q